Initial Oncologic Prices Must Factor In Future Changes In Dosing – Bristol
Executive Summary
Manufacturers should take into account potential differences in dosing for future indications when setting prices for novel oncologics, Bristol-Myers Squibb CFO Andrew Bonfield said June 15